Advertisement

Traitements médicamenteux de la migraine de l’enfant et de l’adolescent

  • D. AnnequinEmail author

Résumé

Les médicaments de la migraine de l’enfant ont donné lieu depuis une dizaine d’années à plusieurs études. Ces données nous permettent de donner des recommandations claires et précises pour le traitement de crise contrairement au traitement de fond où aucun consensus n’apparaît.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Fernandes R, Ferreira JJ, Sampaio C (2008). The placebo response in studies of acute migraine. J Pediatr 152(4): 527–33, 533PubMedCrossRefGoogle Scholar
  2. 2.
    Lewis DW, Winner P, Wasiewski W (2005). The placebo responder rate in children and adolescents. Headache 45(3): 232–9PubMedCrossRefGoogle Scholar
  3. 3.
    Headache classification subcommittee of the International Headache Society (2004). The international classification of headache disorders 2nd edition. Cephalalgia 24. Suppl 1Google Scholar
  4. 4.
    AFSSAPS (2009). Prise en charge médicamenteuse de la douleur aiguë et chronique chez l’enfant. Recommandations de bonne pratique (RBP)Google Scholar
  5. 5.
    Ho TW, Pearlman E, Lewis D et al. (2012). Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia 32(10): 750–65PubMedCrossRefGoogle Scholar
  6. 6.
    Hewitt DJ, Pearlman E, Hamalainen M et al. (2012). Long-Term Open-Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs. Headache 18(10) 4610Google Scholar
  7. 7.
    McDonald SA, Hershey AD, Pearlman E et al. (2011). Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. Headache 51(9): 1374–87PubMedCrossRefGoogle Scholar
  8. 8.
    Eiland LS, Jenkins LS, Durham SH (2007). Pediatric migraine: pharmacologic agents for prophylaxis. Ann Pharmacother 41(7): 1181–90PubMedCrossRefGoogle Scholar
  9. 9.
    Lewis DW, Diamond S, Scott D, Jones V (2004). Prophylactic treatment of pediatric migraine. Headache 44 (3, 230–237PubMedCrossRefGoogle Scholar
  10. 10.
    Lewis D, Ashwal S, Hershey A et al. (2004). Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 28; 63(12): 2215–24CrossRefGoogle Scholar
  11. 11.
    Damen L, Bruijn J, Verhagen AP et al. (2006). Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. Cephalalgia 26(5): 497–505PubMedCrossRefGoogle Scholar
  12. 12.
    Sorge F, De SR, Marano E et al. (1988). Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia 8(1): 1–6PubMedCrossRefGoogle Scholar
  13. 13.
    Sorge F, Marano E (1985). Flunarizine v. placebo in childhood migraine. A double-blind study. Cephalalgia 5. Suppl 2: 145–8PubMedGoogle Scholar
  14. 14.
    ANAES (2003). Prise en charge diagnostique et thérapeutique de la migraine chez l’adulte et l’enfant. Aspects cliniques et économiques. Recommandations pour la pratique cliniqueGoogle Scholar
  15. 15.
    Winner P, Pearlman EM, Linder SL et al. (2005). Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 45(10): 1304–12PubMedCrossRefGoogle Scholar
  16. 16.
    MacLennan SC, Wade FM, Forrest KM et al. (2008). High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23(11): 1300–4PubMedCrossRefGoogle Scholar
  17. 17.
    Bruijn J, Duivenvoorden H, Passchier J et al. (2010). Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 30(12): 1426–34PubMedCrossRefGoogle Scholar
  18. 18.
    Abu-Arafeh I (2012). Flunarizine for the prevention of migraine — a new look at an old drug. Dev Med Child Neurol 54(3): 204–5PubMedCrossRefGoogle Scholar
  19. 19.
    Lewis D, Winner P, Saper J et al. (2009). Randomized, double-blind, placebo-controlled study to evaluate the Efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 123(3): 924–34PubMedCrossRefGoogle Scholar
  20. 20.
    Tepper SJ (2012). Opioids should not be used in migraine. Headache 52. Suppl 1: 30–4PubMedCrossRefGoogle Scholar
  21. 21.
    Trautmann E, Lackschewitz H, Kroner-Herwig B (2006). Psychological treatment of recurrent headache in children and adolescents: a meta-analysis. Cephalalgia 26(12): 1411–26PubMedCrossRefGoogle Scholar
  22. 22.
    Lewis DW, Diamond S, Scott D, Jones V (2004). Prophylactic treatment of pediatric migraine. Headache 44(3): 230–7PubMedCrossRefGoogle Scholar
  23. 23.
    Silver S, Gano D, Gerretsen P (2007). Acute treatment of paediatric migraine: a meta-analysis of Efficacy. J Paediatr Child Health 14Google Scholar
  24. 24.
    Damen L, Bruijn JK, Verhagen AP et al. (2005). Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 116(2): e295–e302PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Paris 2014

Authors and Affiliations

  1. 1.Centre de référence de la migraine de l’enfant et de l’adolescent - Centre de la douleur de l’enfant et de l’adolescentHôpital Armand-Trousseau (AP-HP)Paris Cedex 12France

Personalised recommendations